Generics & Biosimilars

Access, interchangeability, litigation, and pricing dynamics for follow‑ons.

  • 2 Tracked terms
  • Last 30 days Feed window
Search within this topic Ask AI about this topic All topics

What this topic collects on

An article joins this feed when it matches these terms. Each one is also a search of its own.

Latest in Generics & Biosimilars


pearceip.law > 09/28/2026 > tevas-second-denosumab-biosimilar-fda-approved

Teva’s Second Denosumab Biosimilar FDA-Approved

5+ day, 22+ hour ago   (216+ words) Home / News / BioBlast® On 28 September 2026, Teva announced that it has strengthened its position in the biosimilars market with the FDA approval of its internally developed Degevma™ (denosumab-adet), biosimilar to Amgen’s Xgeva®. Degevma™ is indicated for all approved reference indications and…...